IMDX — Insight Molecular Diagnostics Inc.
—
Nasdaq ·
Health Care ·
Life Sciences Tools & Services ·
CIK 1642380 ·
Last close
$6.44
Market Cap
$207.95M
52W High
$6.86
52W Low
$2.42
ADV30
467,532
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 32,000 | 15,000 | -10,331,000 | -4,290,000 | 40,427,000 | 28,201,000 | 51,118,000 |
| Dec 2025 | 1,139,000 | 496,000 | -9,950,000 | -22,955,000 | 25,756,000 | 11,583,000 | 57,220,000 |
| Sep 2025 | 260,000 | 139,000 | -7,670,000 | -10,854,000 | 43,937,000 | 18,692,000 | 53,133,000 |
| Jun 2025 | 518,000 | 350,000 | -6,971,000 | -9,742,000 | 50,517,000 | 24,287,000 | 49,419,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-22,184,000
Investing CF
$-3,185,000
Financing CF
$28,072,000
CapEx
$-3,185,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-1.62
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-400,761,000
Inventory
$446,000
Receivables
$1,128,000
ST Investments
—
EBIT TTM
$-50,113,000
Pretax Income TTM
$-50,222,000
Interest Exp TTM
$109,000
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,949,000
EBITDA
$-32,569,000
Free Cash Flow
$-15,769,625
Enterprise Value
$171,489,744
Total Cash
$28,201,000
Total Debt
$3,069,000
Shares Out
32,290,167
Trailing EPS
$-1.51
Book Value
$-1.10
ROE
—
ROA
-43.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,055,000 | -30,578,000 | -50,222,000 | 25,756,000 | 57,220,000 | — | -22,184,000 |
| Dec 2024 | 1,881,000 | -23,247,000 | -60,663,000 | 35,081,000 | 47,355,000 | — | -20,689,000 |
| Dec 2023 | 1,503,000 | -22,417,000 | -27,781,000 | 74,892,000 | 54,424,000 | — | -23,325,000 |
| Dec 2022 | 958,000 | -28,852,000 | -72,902,000 | 100,091,000 | 65,799,000 | — | -45,568,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.78
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TKNO | Alpha Teknova, Inc. | $213.92M | $3.99 | — |
| MYGN | MYRIAD GENETICS INC | $363.63M | $3.85 | — |
| OABI | OmniAb, Inc. | $369.68M | $2.55 | — |
| MXCT | MAXCYTE, INC. | $107.12M | $1.00 | — |
| NRC | NRC HEALTH | $429.10M | $19.04 | — |
News headlines (Yahoo Finance, 1h cache)
How Insight Molecular Diagnostics (IMDX) Story Is Shifting With Fresh Capital And GraftAssureDx Submission
2026-05-15 13:16 · Yahoo
Insight Molecular Diagnostics Inc (IMDX) Q1 2026 Earnings Call Highlights: Strategic Advances ...
2026-05-14 05:00 · Yahoo
IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization
2026-05-13 20:05 · Yahoo
iMDx to Release First Quarter 2026 Results on May 13, 2026
2026-05-06 20:05 · Yahoo
How The Insight Molecular Diagnostics (IMDX) Story Is Shifting With Funding And GraftAssureDx Milestones
2026-04-29 00:18 · Yahoo
Real-World Evidence and Industry Momentum Builds for iMDx’s Flagship GraftAssure Assay
2026-04-14 12:00 · Yahoo
Why The Insight Molecular Diagnostics (IMDX) Story Is Shifting After Cash Raise And FDA Catalyst
2026-04-13 22:08 · Yahoo
How The Insight Molecular Diagnostics (IMDX) Story Is Shifting With New Funding And FDA Catalyst
2026-03-30 01:05 · Yahoo
Insight Molecular Diagnostics Inc. Q4 2025 Earnings Call Summary
2026-03-27 12:30 · Yahoo
Insight Molecular Diagnostics: Q4 Earnings Snapshot
2026-03-26 20:27 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.